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Stanley J. Korsmeyer
The scientific community has been saddened and dimin-
ished by the loss of Stanley J. Korsmeyer, M.D., who died of
lung cancer last month at the age of 54. Over the last 25 years,
Korsmeyer had been an international leader in the fields of can-
cer biology and programmed cell death (apoptosis).Through his
studies of apoptosis, Korsmeyer helped revolutionize our con-
cepts of carcinogenesis. Korsmeyer, a medical oncologist by
training, also helped translate this knowledge into the develop-
ment of novel cancer therapeutics that are just now entering into
human clinical trials.
Stan didn’t start out to be a research scientist. He grew up
the oldest of four on a livestock farm in southern Illinois. It was
his involvement in the 4-H club that spawned his interest in sci-
ence. From the beginning, his scientific experiments met with
success. The pair of Hampshire Hogs he raised at age 14 were
named Grand Champion at the Illinois State Fair, and Stan went
off to the University of Illinois determined to become a veterinar-
ian. However, on the advice of one of his veterinary mentors, he
switched to pre-med. Following receipt of an M.D. degree from
the University of Illinois and an internship and residency at
UCSF, he arrived at the NIH as a Research Fellow at a time
when molecular biology was just beginning to revolutionize the
study of human disease. There, under the tutelage of scientists
like Tom Waldmann and Phil Leder, Stan soon joined the van-
guard of research scientists characterizing the molecular fea-
tures of the chromosomal translocations that had been
observed in patients with leukemia/lymphoma. Over his career,
Stan contributed to the characterization of a variety of chromo-
somal translocations and identified several widely studied onco-
genes including MLL, AF-4, and Ttg-1 (rhombotin).
Although he had many accomplishments, Stan will be best
known for his contributions to the discovery and characteriza-
tion of the role that programmed cell death plays in the patho-
genesis of cancer. In 1985, the Korsmeyer laboratory was one
of three laboratories to describe the molecular aspects of a
chromosomal translocation between chromosomes 14 and 18
observed in the majority of patients with follicular lymphoma.
This translocation placed the immunoglobulin gene enhancer
from chromosome 14 in close proximity to a previously unchar-
acterized gene on chromosome 18 that was given the name
Bcl-2. From the beginning, Bcl-2 was a problem. It didn’t score
easily in any of the assays usually used to characterize onco-
genes. In 1988, a group from The Walter and Eliza Hall Institute
reported that Bcl-2 could promote the survival of hematopoietic
cells in culture. Shortly thereafter, Korsmeyer, who had been
pursuing an independent investigation to determine whether
Bcl-2 overexpression could alter B cell development and/or
transformation in vivo, confirmed and extended this observa-
tion. Korsmeyer demonstrated that a Bcl-2 transgene expressed
under the control of an immunoglobulin enhancer led to the pro-
gressive accumulation of B cells in vivo. The transgenic B cells
were characterized by an extended cell survival, and this
extended survival led ultimately to an increased incidence of B
cell lymphomas in the mice.These studies provided the first evi-
dence that inhibiting cell death by apoptosis could contribute to
development of cancer.
Following his pioneering discoveries of the role of Bcl-2 in
preventing programmed cell death and in promoting carcino-
genesis, Stan remained at the forefront of apoptosis research.
Not only did he demonstrate that overexpression of Bcl-2 could
enhance lymphocyte survival in vivo, he also demonstrated that
Bcl-2′s endogenous role was to regulate cell survival. He
showed that Bcl-2-deficient mice were unable to maintain the
survival of mature lymphocytes. Bcl-2-deficient animals devel-
oped profound immunodeficiency soon after birth. Korsmeyer
also led investigations to identify how Bcl-2 proteins work. His
laboratory localized Bcl-2 to the mitochondria; discovered Bax,
a Bcl-2 homolog whose function was to execute cells rather
than keep cells alive; and cloned Bad and Bid, two BH3-only-
containing Bcl-2 homologs that modulate the functions of other
family members. In recent years, many others have contributed
to the current understanding of apoptosis regulation, but Stan
continued to be a leading figure. As the Bcl-2 family expanded
to include a dizzying array of death inhibitors and death effec-
tors and their intermolecular regulatory network became
increasingly complex, it was Stan who came up with a simple
model of Bcl-2 function that focused on the family’s central
activity. Stan proposed that the combined activities of Bcl-2-
related proteins acted like a rheostat to regulate a cell’s sensi-
tivity to apoptotic stimuli. He hoped to take advantage of this by
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developing cancer therapeutics specifically designed to either
inhibit the antiapoptotic members or activate the proapoptotic
members.
Stan’s ability to reduce problems to first principles kept the
field’s attention focused on the big picture. Stan’s summation to
a science writer of his interest in the Bcl-2 family said it best: “It
turns out to be a family in which there are good guys and bad
guys.” Last year, Stan’s laboratory collaborated with investiga-
tors in the Harvard Chemistry Department to develop peptide
mimetics of the BH3 proteins that suppress the antiapoptotic
function of Bcl-2. Using a chemical technique called hydrocar-
bon stapling, they replaced the natural amino acids within a
BH3 peptide sequence to produce a stable helical structure with
enhanced killing activity and provided preliminary evidence that
treatment of cultured leukemia cells with these modified pep-
tides led to selective inhibition of leukemic cell survival.
Treatment of mice with leukemia with these new compounds
slowed disease progression. In addition, Stan’s collaboration
with a company he helped found, Idun Pharmaceuticals, and
Abbott Laboratories has led to the development of small mole-
cule inhibitors of antiapoptotic Bcl-2 proteins. These mimetics
appear to shift the Bcl-2 rheostat in favor of the proapoptotic
family members and induce programmed cell death in cancer
cells with elevated levels of antiapoptotic Bcl-2-related proteins.
Ironically, in a paper soon to be published, these new Bcl-2
inhibitors are shown to have single agent activity in treating lung
cancer cells.
As numerous and significant as Stan’s scientific achieve-
ments were, what those of us who worked with him will remem-
ber is the enthusiasm and perspective that he brought to his
research. No matter how competitive the situation, he always
reminded his own laboratory, collaborators, and competitors
that the important goal was to focus on developing a deeper
understanding of cancer and utilize that information to improve
cancer treatment. Stan’s dedication to science was surpassed
only by his dedication and love for his family. Despite being a
nonsmoker, he developed lung cancer. Even his illness couldn’t
change his approach to life. Right through the final stages of his
treatment, he faced his illness with courage and optimism,
actively participating in the choice of therapy he received. Stan
was never one to stay on the sidelines.
Stan’s contributions to cancer research were recognized
widely in his lifetime. He was appointed a tenured Professor,
first at Washington University and then at Harvard. Stan was
appointed an Investigator within the Howard Hughes Medical
Institute at both universities. He was elected to membership of
the National Academy of Sciences, the Institute of Medicine,
and the American Philosophical Society. His awards for cancer
research include the Bristol Meyers Squibb Award for
Distinguished Achievement in Cancer Research, the Charles S.
Mott Prize of General Motor Cancer Research Foundation, the
2000 Louisa Gross Horwitz Prize, the Stratton Medal from the
American Society of Hematology, the Leukemia and Lymphoma
Society deVilliers International Achievement Award, and the
International Award for Cancer Research from the Pezcoller
Foundation and the American Association for Cancer
Research. Nevertheless, those of us who knew him will remem-
ber Stan best for his qualities as a colleague, mentor, and
friend. When Stan Korsmeyer died on March 31, 2005, we lost
one of the good guys.
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